All News
Does Colchicine Lower Gout Mortality Risk?
Data from a large UK database finds that gout patients starting urate-lowering therapy (ULT) will benefit from added colchicine prophylaxis by having fewer cardiovascular events.
Read ArticleEULAR: Considerations when Transitioning from Pediatric to Adult Rheumatologic Care
EULAR has established guidance on best practices for delivering patient education in physical activity and self-management of pain during transitional care in rheumatology.
Anti-Zoster Drug Prevents Shingles in Lupus Patients on Anifrolumab
The antiviral drug valaciclovir (Valtrex), given prophylactically, kept patients with systemic lupus erythematosus (SLE) under treatment with anifrolumab (Saphnelo) from having herpes zoster attacks, researchers said, offering a potential alternative to zoster vaccination.
Read ArticlePhase 3 Trial Results of Deucravacitinib in Psoriatic Arthritis
Bristol Myers Squibb announced recently the results from POETYK PsA-1 and POETYK PsA-2, Phase 3 trials pivotal trials of deucravacitinib (DEUC) in adults with active psoriatic arthritis. Both trials met their primary endpoint, demonstrating ACR20 efficacy after 16 weeks of treatment with DEUC compared with placebo.
Read ArticleICYMI: VITAL Info on Autoimmune Disease (2.9.2024)
Dr. Jack Cush reviews the journal reports from the past week on RheumNow.com. Highlights are summarized by three songs: "Stairway to Heaven", "You're No Good", and "How Long (has this been going on)".
Read ArticleSedentary Behavior Increases the Risk of Gout
NHANES national survey study shows that sedentary behavior is an independent risk factor for gout, especially in those without hyperuricemia.
A Modifiable Vascular Risk in SLE
Atherosclerosis progression was more than twice as common in younger people with SLE than in healthy controls in a prospective study from Greece, but the rate difference narrowed substantially with sustained SLE remission and conventional cardiovascular risk factor management.
Read Article
Dr. John Cush RheumNow ( View Tweet)


